The Signal Detection Process in GVP Module IX for Signal Management

An Introduction to GVP Module IX for Signal Management

A New Option for Safety Signal Management and Pharmacovigilance Workflow

Are Social Media Data used in Pharmacovigilance Biased?

Reducing the Noise from Social Media for Pharmacovigilance

What's Driving Pharmacovigilance Technology Acquisition?

The Value and Validity of Social Media Monitoring in Pharmacovigilance

Depression as a Drug Side-Effect: A Quick FAERS Analysis

Can Modern Analytics be Forced into Traditional Pharmacovigilance Workflow Tools?

Advera Health's Commitment to FAERS Data Quality and Turn Around Time

Social Media Monitoring for Pharmacovigilance and Drug Safety

2018- The Year of Next Gen Drug Safety and Pharmacovigilance 2.0

Analysis of a FDA Safety Signal: DPP-4's and Rhabdomyolysis

Evidex Goes Global - VigiBase Drug Safety Data Access

An Analysis of Adverse Events Associated with Endothelin Receptor Antagonists (ERAs) using FAERS

Santa Rosa Wildfires - A Very Tough Week at Advera Health

FAERS Thee Well - Drug Safety Excitement with FDA Dashboard

How Pharmacovigilance Departments Can Work Smarter, Act Bigger

Case Studies: Signal Detection Utilizing FDA Adverse Event Reporting System (FAERS) Data

What happens when a Safety Signal contradicts Clinical Trial data?

FDA Releases Q1 2017 Drug Safety Watch List: It’s Boring and That’s Good

Canada’s March Toward Mandatory Reporting of Adverse Events by Providers

Failure to Warn: The Week in Drug Safety News

Post-Marketing Drug Safety and Pharmacovigilance Is Now More Important Than Ever

Pharmacovigilance 2.0 – Let Freedom Ring in Philadelphia!

2016 FDA Adverse Event Reporting System (FAERS) Data: An Infographic

Using FAERS to Determine Medical Costs – a Payer Perspective

Calculating the Reporting Rate of Adverse Events in FAERS – A New Methodology

Efficacy vs. Effectiveness - The Role of Pharmacovigilance

A Big Data Stumble in Healthcare

Increasing Pressure for Increased Pharmacovgilance Capabilities

Drug Safety Progressives – The Rise of the Pharmacovigilante

Working Toward a Cure: The Foundation for Sarcoidosis Research

Why Does Adverse Event Reporting to FAERS Continue to Accelerate?

Guest Post: BBK Talks #BigData with Advera Health Analytics

Chronic Underreporting of Clinical Trials

A Crystal Ball for FDA Action: How we Validated RxSignal

Watson Health is the Ultimate Data Parasite

RxSignal 3.0 - Predicting FDA Label Changes

Should Adverse Drug Event Reporting by Healthcare Providers be Mandatory?

FAERS - Myths vs. Realities

OpenFDA – the Good, the Bad, and the Ugly

FDA Releases Updated Drug Safety Data – Announces OpenFDA… Now hold your applause

How Are Post-Approval Adverse Drug Event Data Obtained?